Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Each subject will consume (in a randomized fashion) both the intervention beverage (nitrate solution) and the placebo, separated by a 1 wk washout period. The investigators will test the hypothesis that 7 days of dietary nitrate supplementation will improve metabolic efficiency in patients with COPD compared to the placebo.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Nitrate supplementation | Active Comparator | Sodium nitrate solution |
|
| Placebo supplementation | Placebo Comparator | Sodium chloride solution |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nitrate supplementation | Dietary Supplement | 7 days of supplementation with sodium nitrate solution |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in metabolic efficiency during exercise | Metabolic efficiency (degree of efficiently used energy during exercise) will be assessed during the test days before and after the two supplementation periods (active and placebo) for a total timespan of 3 weeks. | Baseline, day 7, day 14 and day 21. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in blood pressure during exercise | Change in blood pressure will be assessed during the test days before and after the two supplementation periods (active and placebo) for a total timespan of 3 weeks. | Baseline, day 7, day 14 and day 21. |
| Change in dyspnea during exercise |
| Measure | Description | Time Frame |
|---|---|---|
| VO2max and Wmax | Baseline | |
| height, body weight and body mass index (BMI) | Baseline | |
| Fat free mass and fat mass |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Annemie Schols, Prof. | Maastricht University Medical Center | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Maastricht University Medical Center | Maastricht | Limburg | Netherlands |
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo supplementation | Dietary Supplement | 7 days of supplementation with sodium chloride solution |
|
Change in dyspnea will be assessed during the test days before and after the two supplementation periods (active and placebo) for a total timespan of 3 weeks. |
| Baseline, day 7, day 14 and day 21. |
| Change in cycle endurance time during exercise. | Change in cycle endurance time will be assessed during the test days before and after the two supplementation periods (active and placebo) for a total timespan of 3 weeks. | Baseline, day 7, day 14 and day 21. |
| Change in oxygen uptake (VO2 mL/min) during exercise | Change in oxygen uptake will be assessed during the test days before and after the two supplementation periods (active and placebo) for a total timespan of 3 weeks. | Baseline, day 7, day 14 and day 21 |
| Change in Resting Energy Expenditure (REE) | Change in REE will be assessed during the test days before and after the two supplementation periods (active and placebo) for a total timespan of 3 weeks. | Baseline, day 7, day 14 and day 21 |
| Change in plasma concentrations of nitrate and nitrite, glucose, insulin, lactate and free fatty acids, IFABP and cardiac troponin | Change in these plasma concentrations will be assessed during the test days before and after the two supplementation periods (active and placebo) for a total timespan of 3 weeks. | Baseline, day 7, day 14 and day 21 |
Fat free mass and fat mass determined by DEXA-scan |
| Baseline |
| Lung function | Baseline |
| Physical activity | During the two supplementation periods |
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |